• 不 限
  • 期刊论文
  • 硕博论文
  • 会议论文
  • 报 纸
  • 英文论文
  2. 您的位置
  3. 首页
  4. 会议论文
  5. Personalized Medicine Based on the Population Pharmacokinetics of Valproic Acid in Children with Epi

Personalized Medicine Based on the Population Pharmacokinetics of Valproic Acid in Children with Epi

来源 :第四届定量药理学与新药评价国际会议·2013(The 4th International Symposium in Qu | 被引量 : 0次 | 上传用户：numlof
【摘 要】
：
Valproic acid (VPA) is an important drug in treatment of childhood epilepsy, however, VPA concentration should be monitored during epilepsy treatment.The aim of this study was to realize personalized
【作 者】
：
Xingang Li Yueting Zhu Zhigang Zhao 
【机 构】
：
Department of Pharmacy, Beijing Tiantan Hospital Affiliated to Capital Medical University, Beijing,1
【出 处】
：
第四届定量药理学与新药评价国际会议·2013(The 4th International Symposium in Qu
【发表日期】
：
2013年4期
下载到本地 , 更方便阅读
下载此文 赞助VIP
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
　　Valproic acid (VPA) is an important drug in treatment of childhood epilepsy, however, VPA concentration should be monitored during epilepsy treatment.The aim of this study was to realize personalized medicine on the basis of population pharmacokinetics (PopPK) of VPA in children with epilepsy.
其他文献
Assessing ethnic sensitivity by simulating pharmacokinetics in virtual Caucasian and Chinese populat
Background and Rationale: Physiologically-based pharmacokinetics (PBPK) modelling is a key component of model-based drug development and is increasingly embraced within the industry and regulatory aut
会议
Model-Based Drug Development for Oncology Protein Therapeutics
Biopharmaceutical industry has focused on cancer drug research and development in the past decades, however the success rate for oncology products is relatively low compared to other therapeutic areas
会议
Pharmacokinetic profile of ranibizumab is similar between Chinese and Caucasian patients with diabet
Purpose:Diabetic macular edema (DME) is a trequent manifestation of diabetic retinopathy which is the most common microvascular complications of diabetes mellitus, accounting for 13％ visual impairment
会议
Population pharmacokinetic/pharmacodynamic Modeling for Pegylated Recombinant Human Growth Hormone (
Objective:CPRC-Y is a pegylatedrecombinant human growth hormone (rhGH) developed with the aim of reducing serum clearance and thereby prolonging the exposure leading to once-weekly sc administration.T
会议
E2HSA, an albumin-Exendin-4 conjugate, showed a dose-dependent effect on insulin secretion in health
Aim:To assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single, escalating subcutaneousinjections of an albumin-Exendin-4 conjugate in healthy rhesus monkeys.Methods:This stud
会议
Predicting whole blood concentrations of zonisamide in human using a physiologically based pharmacok
Background:Concentration dependent Blood to plasma ratio (B/P) of zonisamide(ZNS) was observed in clinical trial, which requires measuring both plasma concentration and whole blood concentration for c
会议
Mechanism-Based Pharmacokinetic-Pharmacodynamic-Disease Progression Model for Perindopril in Spontan
The aim of the present study was to development a pharmacokinetic/pharmacodynamic (PK/PD) model for the characterization ofperindopril effect in spontaneously hypertensive rats (SHRs) while taking int
会议
A disease progression model for Alzheimer's disease
Background: The aim of this study was to establish a causal disease progression model quantifying the sequential change of biomarkers and their relative values as predictors of different Alzheimers Di
会议
Alzheimer's diseaseCSFAβ42p-tauhippocampus volumeclinical scoreNONMEM
Population Pharmacokinetics-pharmacodynamics modeling of risperidone and its active metabolite in Ch
Background: Risperidone, an anatypical antipsychotic agent, characterized as an antagonist of dopaminergic and serotonergic receptors, is now widely used in the treatment of patients with positive sym
会议
Application of Model-Based Methods to Characterize Exenatide-Loaded Double-Walled Microspheres: In V
Exenatide (glucagon-like-peptide-1 analogue) was authorized for marketing in the European Union in November 2006 and was approved by FDA in April 2005.To improve compliance, exenatide double-walled mi
会议